IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide, yet until recently, treatment has been largely limited to supportive care. However, the treatment landscape is rapidly evolving as new targeted therapies with novel mechanisms of action emerge. Don’t miss the chance to hear from two leading IgAN experts as they share practical insights on integrating these novel therapies into clinical practice and developing personalized treatment strategies for patients in this new era of care. Through this educational activity, you have the opportunity to earn a maximum of 1.25 CE credits in total. To achieve this, you can complete the PRIME on-demand video to earn 0.25 CE credits. Additionally, if you choose to engage with the SynopsiMedEd Related Evidence articles, you can earn an extra 1 CE credit. If you decide not to engage with these articles, you can still claim partial credit based on your level of participation. Total Possible Credits: 1.25 CE Credits from PRIME On-Demand Video: 0.25 CE Credits from SynopsiMedEd Related Evidence: 1 CE
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/preparing-new-era-targeted-treatments-iga-nephropathy
- Start Date: 2024-09-27 05:00:00
- End Date: 2024-09-27 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.25 hours
AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 12500.0 - Is Kind Support: False Source: Otsuka America Pharmaceutical, Inc. - Amount: 18625.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all